Relugolix for the treatment of uterine fibroids.

• Fabio Barra ; M. Seca ^[1] ; L. Della Corte ^[2] ; Giampaolino, P. ^[2] ; Simone Ferrero
  1. [1] University of Genoa

     University of Genoa

     Genoa, Italia

     
  2. [2] University of Naples Federico II

     University of Naples Federico II

     Nápoles, Italia

     
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 8, 2019 (Ejemplar dedicado a: Agosto), págs. 503-512
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Uterineleiomyomasrepresentthemostcommonform of benign gynecological tumors affecting 20-40% of women during their life. Several therapeutic options are available for treating these patients. The use of medical treatment for myomas has largely grown in the last years, in particular for women who would refuse, postpone or are not candidates for surgery. In the last years, the clinical investigation of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ants) has emerged. This class of drugs exerts pure competitive antagonistic activity on the GnRH receptor at the pituitary gland, producing an immediate stop in the release of gonadotropins and sex steroids. Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas. Currently, several phase III clinical trials are ongoing to evaluate this molecule in this setting in the U.S. and Europe.